Wechselwirkungen · Komboglyze
Komboglyze 2.5 mg/850 mg film-coated tablets Komboglyze 2.5 mg/1,000 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-213480 · Präparat HOS-155120
The metabolism of saxagliptin is primarily mediated by cytochrome P450 3A4/5 (CYP3A4/5). In in vitro studies, saxagliptin and its major metabolite neither inhibited CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 3A4, nor induced CYP1A2, 2B6, 2C9, or 3A4. In studies conducted in healthy subjects, neither the pharmacokinetics of saxagliptin nor its major metabolite, were meaningfully altered by metformin, glibenclamide, pioglitazone, digoxin, simvastatin, omeprazole, antacids or famotidine. In addition, saxagliptin did not meaningfully alter the pharmacokinetics of metformin, glibenclamide, pioglitazone, digoxin, simvastatin, the active components of a combined oral contraceptive (ethinyl estradiol and norgestimate), diltiazem or ketoconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) norgestimate (HOS-110544) ketoconazole (HOS-084513) simvastatin (HOS-086158) famotidine (HOS-112087) digoxin (HOS-086172) ethinyl estradiol (HOS-088135) pioglitazone (HOS-089663) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-23T16:24:00Z · SHA-256 49284a2aa4bf5d4cc65df4fbea1683957d8ce0be034c6bcc4568504417c45a17 · Passage b48610bb84b0ef0ac38754d2f1349c2cf131d2833d40e888421beab34af131d9 · Zeichen 538–1289 im Abschnitt